The Globe and Mail reports in its Friday, April 25, edition that Canaccord Genuity analyst Doug Taylor started coverage on Healwell AI with a "speculative buy" ranking and a $2.50 share target. The Globe's David Leeder writes in the Eye On Equities column that analysts on average target the shares at $3.66. Mr. Taylor says in a note: "The company has emerged from a series of transactions, culminating with the recently completed Orion acquisition that we project transforms Healwell AI into a profitable pure-play on the theme of artificial intelligence applied to improving healthcare outcomes. This is delivered through a platform that brings together emerging high-growth artificial intelligence technologies with more traditional clinical services businesses to improve outcomes for patients, healthcare systems, and the life sciences companies servicing them. We rate the company as 'speculative' as its strategy requires the company to depend on transactions (financing and M&A) that support this vision in an accretive manner. Such models inherently carry a higher risk profile until the M&A program and self-funding motion are better established."